Gaber Y, Siemens H J, Schmeller W
Department of Dermatology, Medical University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany.
Br J Dermatol. 2001 Mar;144(3):546-8. doi: 10.1046/j.1365-2133.2001.04081.x.
Activated protein C (APC) resistance is the most frequently diagnosed heritable thrombophilic defect predisposing to thrombosis.
To determine the prevalence of APC resistance due to factor V Leiden mutation in patients with leg ulcers.
Within a 2-year-period 100 consecutive patients with leg ulcers were examined for factor V Leiden mutation.
APC resistance due to factor V Leiden mutation was detected in 19 of 53 patients (36%) with post-thrombotic leg ulcers and in three of 47 patients (6%) with ulcers caused by primary varicosis. In a healthy control group APC resistance due to factor V Leiden mutation was found in five of 96 (5%) volunteers.
In view of this high prevalence of APC resistance of 36%, which has never previously been reported, patients with post-thrombotic leg ulcers should be investigated for APC resistance.
活化蛋白C（APC）抵抗是最常被诊断出的遗传性易栓缺陷，易引发血栓形成。
确定腿部溃疡患者中因因子V莱顿突变导致的APC抵抗的患病率。
在两年时间内，对100例连续的腿部溃疡患者进行因子V莱顿突变检测。
在53例血栓形成后腿部溃疡患者中，有19例（36%）检测到因因子V莱顿突变导致的APC抵抗；在47例原发性静脉曲张引起的溃疡患者中，有3例（6%）检测到该抵抗。在一个健康对照组中，96名志愿者中有5名（5%）检测到因因子V莱顿突变导致的APC抵抗。
鉴于此前从未报道过的36%的高APC抵抗患病率，应对血栓形成后腿部溃疡患者进行APC抵抗检测。
